[#item_full_content]
中国生物制药(01177.HK)库莫西利联合氟维司群治疗HR+/HER2-晚期乳腺癌III期数据公布
2024-09-29T07:22:13-04:00September 29th, 2024|
Related Posts
-
日清食品(01475.HK)拟3370万澳元收购澳洲冷冻饺子生产商
September 29th, 2024 -
李家超到访沙田区就施政报告听取民意
September 29th, 2024 -
澜起科技:公司产品暂不涉及手机
September 29th, 2024 -
星凯控股(01166.HK)年度股东应占亏损同比收窄49.78%
September 29th, 2024